Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHRP-6 is used experimentally to produce strong GH surges and hyperphagia, allowing investigation of GH-dependent anabolism and energy-balance regulation2030, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While GHRP-6 works as a first-generation synthetic hexapeptide ghrelin mimetic that potently stimulates GH release and markedly increases appetite via GHSR-1a activation in hypothalamus and pituitary203096, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
GHRP-6
GHSR
Liraglutide
GCG
Both peptides fall into a similar broad context as Hormone peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while GHRP-6 is more of a hormone peptide and Liraglutide is better described as a metabolic peptide. Both appear to work through Receptor agonist, but the functional emphasis still separates, with GHRP-6 leaning toward Anabolic growth and Liraglutide leaning toward Metabolic regulation. GHRP-6 has a more synthetic design origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with GHRP-6 in Preclinical development while Liraglutide is approved. GHRP-6 takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, GHRP-6 carries d-amino acid substitution and amidation features, while Liraglutide instead reflects palmitoylation changes; while their sequence patterns also diverge, with GHRP-6 showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.